Gyre Therapeutics presents integrated pipeline for fibrosis, inflammatory diseases and cancer

Gyre Therapeutics filed an 8-K with a presentation outlining its fully-integrated biopharmaceutical platform combining operations with Cullgen Inc., featuring multiple product candidates across fibrosis, inflammatory and oncology indications. The filing details clinical development plans and timelines for candidates including CG923308, F528, CG620953, and others, relevant to investors evaluating the company's pipeline advancement and market opportunities.